O'Nuallain Brian, Allen Amy, Ataman Demet, Weiss Deborah T, Solomon Alan, Wall Jonathan S
Human Immunology and Cancer/Alzheimer's Disease and Amyloid-Related Disorders Research Program, Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, Tennessee 37920, USA.
Biochemistry. 2007 Nov 13;46(45):13049-58. doi: 10.1021/bi701255m. Epub 2007 Oct 18.
Amyloid fibrils and partially unfolded intermediates can be distinguished serologically from native amyloidogenic precursor proteins or peptides. In this regard, we previously had reported that mAb 11-1F4, generated by immunizing mice with a thermally denatured variable domain (VL) fragment of the human kappa4 Bence Jones protein Len, bound to a non-native conformational epitope located within the N-terminal 18 residues of fibrillar, as well as partially denatured, Ig light chains (O'Nuallain, B., et al. (2006) Biochemistry 46, 1240-1247). To define further the antibody binding site, we used random peptide phage display and epitope mapping of VL Len using wild-type and alanine-mutated Len peptides where it was shown that the antibody epitope was reliant on up to 10 of the first 15 residues of protein Len. Comparison of Vkappa and Vlambda N-terminal germline consensus sequences with protein Len and 11-1F4-binding phages indicated that this antibody's cross-reactivity with light chains was related to an invariant proline at position(s) 7 and/or 8, bulky hydrophobic residues at positions 11 and 13, and additionally, to the ability to accommodate amino acid diversity at positions 1-4. Sequence alignments of the phage peptides revealed a central proline, often flanked by aromatic residues. Taken together, these results have provided evidence for the structural basis of the specificity of 11-1F4 for both kappa and lambda light chain fibrils. We posit that the associated binding site involves a rare type VI beta-turn or touch-turn that is anchored by a cis-proline residue. The identification of an 11-1F4-related mimotope should facilitate development of pan-light chain fibril-reactive antibodies that could be used in the diagnosis and treatment of patients with AL amyloidosis.
淀粉样纤维和部分未折叠中间体可通过血清学方法与天然淀粉样前体蛋白或肽区分开来。在这方面,我们之前曾报道,用人类κ4本斯·琼斯蛋白Len的热变性可变结构域(VL)片段免疫小鼠产生的单克隆抗体11-1F4,可与位于纤维状以及部分变性的Ig轻链N端18个残基内的非天然构象表位结合(O'Nuallain, B., 等人,(2006) Biochemistry 46, 1240 - 1247)。为了进一步确定抗体结合位点,我们使用了随机肽噬菌体展示以及对VL Len进行表位作图,使用野生型和丙氨酸突变的Len肽,结果表明抗体表位依赖于蛋白Len前15个残基中的多达10个残基。将Vκ和Vλ N端种系共有序列与蛋白Len和与11-1F4结合的噬菌体进行比较表明,该抗体与轻链的交叉反应性与第7和/或8位的不变脯氨酸、第11和13位的大体积疏水残基有关,此外,还与1 - 4位容纳氨基酸多样性的能力有关。噬菌体肽的序列比对揭示了一个中心脯氨酸,其两侧通常为芳香族残基。综上所述,这些结果为11-1F4对κ和λ轻链纤维特异性的结构基础提供了证据。我们推测相关的结合位点涉及一种罕见的VI型β-转角或接触转角,由一个顺式脯氨酸残基锚定。鉴定与11-1F4相关的模拟表位应有助于开发可用于诊断和治疗AL淀粉样变性患者的泛轻链纤维反应性抗体。